Illinois Appeals Court Affirms $45 Million J&J Talc Verdict, Upholds Survival Act Damages

Illinois Appeals Court Affirms $45 Million J&J Talc Verdict, Upholds Survival Act Damages

On July 10, 2026, a divided Illinois Appellate Court, First District, affirmed a roughly $45 million verdict for the family of Theresa Garcia, who died of mesothelioma at 53 after decades of using Johnson & Johnson baby powder, in a ruling that upholds a $30 million shortened-life-expectancy award under the Illinois Survival Act (2026 IL App (1st) 242199).

Information last verified on July 16, 2026. This is a developing story; we update it as the record changes.

Jurisdiction scope: This article covers an Illinois appellate ruling interpreting the Illinois Survival Act and the Illinois Wrongful Death Act. It does not address talc or asbestos verdicts decided under other states' laws or in federal bankruptcy proceedings involving Johnson & Johnson affiliates.

What Happened

A three-justice panel of the Illinois Appellate Court, First District, affirmed a Cook County jury's roughly $45 million verdict in favor of the estate and family of Theresa Garcia. The consolidated appeal, captioned Salcedo v. Cyprus Amax Minerals Company and cited as 2026 IL App (1st) 242199 (Nos. 1-24-2199 and 1-24-2273 consolidated), was decided on July 10, 2026.

Garcia used Johnson's Baby Powder on herself and her children for most of her life. She was diagnosed with mesothelioma in 2020 and died six months later at age 53. At trial, her family presented expert causation testimony that asbestos in the talc-based product was a substantial factor in causing her disease. A Cook County jury returned a verdict in April 2024 awarding Garcia's six children roughly $12 million under the Illinois Wrongful Death Act and roughly $33 million under the Illinois Survival Act, of which about $30 million compensated Garcia's estate for her shortened life expectancy.

On appeal, Johnson & Johnson argued the trial court should have entered judgment in its favor or ordered a new trial. It challenged three things specifically: the admissibility and sufficiency of the plaintiff's expert testimony on causation, the trial court's award of statutory prejudgment interest, and the jury's finding that Johnson & Johnson Holdco (NA) Inc. and Kenvue Inc., corporate entities created through Johnson & Johnson's 2023 consumer health spinoff, could be held liable as successors to the company that made and sold the talc product Garcia used. The panel rejected each argument and affirmed the verdict in full, including the successor liability finding tying Holdco and Kenvue to the historical Cyprus Amax Minerals-related talc supply chain.

The panel split on one issue: whether Illinois law permits a shortened-life-expectancy award under the Survival Act to go to the estate of someone who was already deceased by the time of trial, rather than only to a living plaintiff. Justice Michael Hyman, writing for the majority and joined by Justice Aurelia Pucinski, held that nothing in Illinois statutory law or prior appellate precedent limits shortened-life-expectancy damages to living plaintiffs. Justice Celia Gamrath concurred in the result on most issues but dissented on that point, warning that the majority's approach would effectively make shortened-life-expectancy damages a routine component of any survival action paired with a wrongful death claim.

Johnson & Johnson has indicated it will pursue further review, with counsel saying the company remains confident that a higher court will find the law does not permit the recovery allowed here. A further appeal, most likely a petition for leave to appeal to the Illinois Supreme Court, has not been decided as of this writing.

What the Law Actually Says

Illinois treats a wrongful death and a survival claim as two distinct legal theories that can be pursued together in the same case, and this ruling turns on the difference between them.

The Illinois Wrongful Death Act, 740 ILCS 180/1, lets certain family members recover for the losses the death itself caused them, including loss of the decedent's income, society, and companionship. That claim belongs to the surviving family members and compensates them for what they lost when their relative died. Readers researching how this claim generally works can see our overview of Illinois wrongful death law.

The Illinois Survival Act, 755 ILCS 5/27-6, works differently. It does not create a new claim for the family. Instead, it allows the decedent's estate to pursue whatever personal-injury claim the decedent could have brought had she lived, including claims for the injury she actually suffered before she died. Courts applying the Survival Act have long allowed estates to recover for a decedent's pain and suffering, medical bills, and lost income up to the date of death. The shortened-life-expectancy theory at issue in this case goes a step further: it treats the reduction in the decedent's remaining life expectancy, caused by the fatal disease, as its own compensable injury under the survived claim, even though the person is no longer alive to experience the years that theory measures. That is the piece Justice Gamrath's dissent said stretches the statute past its intended scope, while the majority found no Illinois authority limiting the theory to living plaintiffs.

Successor liability was the second major issue. Johnson & Johnson restructured its talc liabilities over several years, eventually spinning off its consumer health business as Kenvue and creating other holding entities. The panel affirmed the jury's finding that these successor entities remain answerable for liabilities tied to the predecessor company's talc products and to the historical asbestos-mining supply chain associated with Cyprus Amax Minerals-related parties, rejecting arguments that the corporate restructuring cut off that liability.

This case sits inside a much larger, ongoing body of litigation over talc products and asbestos exposure. Thousands of claims nationwide allege that talc-based personal care products were contaminated with asbestos and caused mesothelioma or ovarian cancer in long-term users; some of that litigation has also intersected with bankruptcy proceedings involving Johnson & Johnson affiliates. Readers can review our broader explainers on the talcum powder lawsuit landscape, the mesothelioma and asbestos lawsuit process, and other pending claims tracked on our mass tort hub.

Analysis: Why This Matters

The following is analysis from the Recording Law Editorial Team.

An appellate affirmance carries more weight than a jury verdict alone because it means a panel of judges reviewed the trial record for legal error and found none serious enough to disturb the result. That is true here across several fronts at once: the sufficiency of the causation expert testimony, the prejudgment interest calculation, and the successor liability theory tying Kenvue and Holdco to the original talc business.

The shortened-life-expectancy ruling is the part of this decision most likely to draw attention beyond this single case. By holding that a deceased plaintiff's estate can recover a large, separate damages category for the years of life the disease took from her, on top of the family's own wrongful death recovery, the majority opinion gives talc plaintiffs' counsel in other Illinois cases a precedent to point to when structuring damages claims involving Survival Act theories. It is also, by the same token, the specific holding Johnson & Johnson has said it intends to challenge further, and the point Justice Gamrath's dissent flagged as the one most likely to expand how these claims are valued going forward.

None of this resolves how a further appeal will come out, and the underlying verdict remains subject to whatever review process follows. What the affirmance does establish, for now, is that this particular combination of a large Survival Act award layered on top of a wrongful death award survived a full round of appellate scrutiny in the First District.

How This Affects You

If you or a family member has been diagnosed with mesothelioma or another asbestos-related disease and is considering a claim in Illinois, it is worth understanding that Illinois law generally treats two different categories of damages as available in the same case: what the injured person's estate can recover for the injury itself, potentially including claims tied to how much the disease shortened the person's expected lifespan, and what surviving family members can separately recover for their own losses from the death. These are legally distinct categories with different statutory sources, and how they apply depends on the specific facts of a case and how it is litigated.

This ruling does not change the underlying facts any individual claimant would need to prove, such as which products were used, over what period, and what a qualified medical expert says about causation. It also does not guarantee any particular outcome in a future case, in Illinois or elsewhere, since this decision may still be reviewed further and other states apply their own wrongful death and survival statutes. Anyone evaluating a potential claim should discuss the specific facts of their situation and the applicable deadlines with a licensed attorney in their jurisdiction.

This article provides general legal information about a specific Illinois appellate court ruling and does not constitute legal advice for any individual case. It covers Illinois law under the Illinois Survival Act and Illinois Wrongful Death Act as of July 16, 2026. This is a developing story: the underlying ruling may be subject to further appeal, and details may change as the record develops. Anyone with a potential claim should consult a licensed attorney in their jurisdiction.

Last updated: 2026-07-16. This is a developing story; details verified as of 2026-07-16.